T
here are more than a dozen receptor subtypes for serotonin (5-hydroxytryptamine, 5-HT), but only 2 of them are generally well known to clinical psychopharmacologists 1 : the 5-HT 1A receptor, stimulation of which is linked to antidepressant and anxiolytic actions, and the 5-HT 2A receptor, blockade of which is linked to the reduction of extrapyramidal side effects and other side effects of the secondgeneration atypical antipsychotics. 1, 2 Now comes the 5-HT 7 receptor onto the scene, 2-17 not just because of the development of specific compounds allowing characterization of this receptor, 3, 5, [7] [8] [9] but also because of the discovery that several of the known antidepressants and antipsychotics block 5-HT 7 receptors, and that this 5-HT 7 antagonism may account in part for the therapeutic properties of these drugs, especially antidepressant actions. [10] [11] [12] [13] [14] [15] [16] [17] Localization and Function of 5-HT 7 Receptors Serotonin-7 receptors are postsynaptic G protein-linked receptors that may regulate serotonin-glutamate interactions. 3, 4, 7 They are distributed in areas that explain their functions, namely, the suprachiasmatic nucleus of the hypothalamus; the hippocampus, cortex, and thalamus; and also in the midbrain raphe nuclei, probably on GABA interneurons or on glutamate terminals. 3, 4, 7 Numerous animal studies have demonstrated the role of 5-HT 7 receptors in preclinical antidepressant actions, learning, memory, sleep, and circadian rhythms.
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5-HT 7 Receptors as Novel Therapeutic Targets
Although no selective 5-HT 7 compounds are available for clinical use, numerous compounds are sufficiently potent blockers of 5-HT 7 receptors such that 5-HT 7 antagonism could theoretically contribute to their pharmacologic actions (Table 1) . [10] [11] [12] [13] [14] [15] [16] [17] In particular, several of the compounds listed in Table  1 are effective antidepressants, and in animal models, the antidepressant efficacy of aripiprazole is reversed in animals lacking 5-HT 7 receptors, 8 and the serotonin release and antidepressant actions of selective serotonin reuptake inhibitors (SSRIs) are enhanced by selective 5-HT 7 antagonists. 3, 5, 8 Three novel agents characterized as antipsychotics have 5-HT 7 antagonist properties among their most potent pharmacologic actions ( Figure  1) , 2,10,13,14 and 1 of these, lurasidone, in late-stage clinical development as an antipsychotic, is actually "5-HT 7 preferring, " with 5-HT 7 antagonism its most potent property. 13 Of these, amisulpride (not available in the United States) is a proven antidepressant. 1, 2, 14 Theoretically, because of their even greater potency for 5-HT 7 antagonism, lurasidone and asenapine are good candidates for clinical testing as antidepressants as well.
Combining agents such as lurasidone or asenapine with SSRIs would be predicted to enhance 5-HT release as well as to have antidepressant properties. [3] [4] [5] 8 Given the recent positive results as an antidepressant for the melatonergic/ serotonergic agent agomelatine, which resets circadian rhythms, 18 combining novel 5-HT 7 antagonists with melatonin agonism may also enhance the antidepressant actions of 5-HT 7 antagonists. In addition, preclinical studies 3, 5, 8, 9 suggest the possibility that agents with potent 5-HT 7 antagonism may improve cognition, so cognition in depression, schizophrenia, and other illnesses is a theoretically attractive clinical target, for 5-HT 7 antagonists as well. 
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The 5-HT ◆ 7 receptor is a novel serotonin receptor whose properties have recently been characterized. Serotonin-7 receptors are localized in cortex, hippocampus, hypothalamus, thalamus, and brainstem raphe nuclei, ◆ where they regulate mood, circadian rhythms, sleep, learning, and memory.
Several known antipsychotics and antidepressants with multifunctional pharmacologic actions have been recently ◆ discovered also to block 5-HT 7 receptors, and this mechanism could hypothetically be linked in part to their antidepressant actions. 
